Both contain Semaglutide. Ozempic up to 2mg - approved for type 2 diabetes. Wegovy 2.4mg - approved for weight management. Wegovy's higher dose leads to greater weight loss (14.9% vs 4-6%).

Both contain Semaglutide. Ozempic up to 2mg - approved for type 2 diabetes. Wegovy 2.4mg - approved for weight management. The higher Wegovy dose produces greater weight loss (14.9% vs 4-6%).

Mounjaro (Tirzepatide) is more effective for weight loss: up to 20.9% vs 14.9% for Wegovy. Mounjaro is a dual agonist - GLP-1 + GIP. The SURMOUNT-5 trial (2024) demonstrated Tirzepatide's superiority. However: Ozempic has the proven SELECT trial (cardiovascular protection). Full comparison here →

Mounjaro (Tirzepatide) is more effective for weight loss: up to 20.9% vs 14.9% for Wegovy. Mounjaro is a dual agonist - GLP-1 + GIP. SURMOUNT-5 (2024) confirmed Tirzepatide superiority. But: Ozempic has the proven SELECT trial (cardiovascular protection). Full comparison here →

STEP-4 (NEJM 2021): after stopping, on average 2/3 of the lost weight returns within a year. GLP-1 treats the symptom (high appetite), not the cause. Lifestyle change - Zone 2, nutrition, sleep - during treatment is critical for maintaining long-term results.

STEP-4 study (NEJM 2021): after stopping, on average 2/3 of lost weight returns within one year. GLP-1 treats the symptom (elevated appetite), not the root cause. Lifestyle changes - Zone 2, diet, sleep - during treatment are critical for long-term results.

SELECT followed patients for 5 years with no new safety signals. Common effects: nausea (44%), diarrhea (30%) - most resolve within 4-8 weeks. Rare effects: pancreatitis (a small increase). Important: close medical supervision, especially in the first year.

SELECT followed patients for 5 years with no new safety signals. Common effects: nausea (44%), diarrhea (30%) - most resolve within 4-8 weeks. Rare: pancreatitis (small increased risk). Important: close medical supervision, especially in the first year.